A Study of VB-111 With Paclitaxel vs Paclitaxel for Treatment of Recurrent Platinum-Resistant Ovarian Cancer (OVAL)
The purpose of this phase 3, randomized, multicenter study is to compare VB-111 and paclitaxel to placebo and paclitaxel in adult patients with Recurrent Platinum-Resistant Ovarian Cancer.
Recurrent Platinum Resistant Ovarian Cancer
DRUG: VB-111 + Paclitaxel|DRUG: Placebo + Paclitaxel
Overall Survival, From randomization until death from any cause (up to 5 years after last study treatment)|Progression Free Survival (PFS) by RECIST 1.1, From randomization until progression defined according to RECIST 1.1 or death, whichever occurs first (up to 5 years after last study treatment)
Combined CA-125 and RECIST 1.1 response (GCIG), From date of study entry until the date of death from any cause, or up to 5 years after last study treatment|CA-125 Response (GCIG), From date of study entry until the date of death from any cause, or up to 5 years after last study treatment|Objective response rate (ORR) by RECIST 1.1, From date of study entry until the date of death from any cause, or up to 5 years after last study treatment|OS100 for a sensitivity analysis of OS, From 100 days after date of study entry until the date of death from any cause, or up to 5 years after last study treatment
The purpose of this phase 3, randomized, multicenter study is to compare VB-111 and paclitaxel to placebo and paclitaxel in adult patients with Recurrent Platinum-Resistant Ovarian Cancer.